Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices by Capricor Therapeutics, Inc. and its officers or directors [1]. Group 1: Company Developments - On May 5, 2025, Capricor announced that the FDA confirmed its intent to hold an advisory committee meeting regarding the Biologics License Application for deramiocel, a treatment for Duchenne muscular dystrophy cardiomyopathy [3]. - Following this announcement, Capricor's stock price dropped by $3.00 per share, or 29.13%, closing at $7.30 per share on May 6, 2025 [4]. - On June 20, 2025, it was reported that the FDA canceled the advisory committee meeting due to concerns about the drug's efficacy and safety, leading to a further decline in Capricor's stock price by $3.68 per share, or 30.82%, closing at $8.26 per share [4]. Group 2: Legal and Investigative Actions - Pomerantz LLP, a firm specializing in corporate, securities, and antitrust class litigation, is leading the investigation into Capricor's practices [5]. - The firm has a history of recovering significant damages for victims of securities fraud and corporate misconduct [5].

Core Insights - Pomerantz LLP is investigating claims on behalf of Tesla investors regarding potential securities fraud or unlawful business practices by the company and its officers [1][3] - Tesla launched its robotaxi service on June 22, 2025, but faced scrutiny from the NHTSA due to reports of erratic driving behavior from the robotaxis, leading to a significant drop in Tesla's stock price [3] Group 1 - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud [4] - The NHTSA's investigation into Tesla was prompted by numerous online videos showing the robotaxis violating traffic laws, which has raised concerns among investors [3] Group 2 - The investigation by Pomerantz LLP indicates potential legal challenges for Tesla, which could impact investor confidence and the company's market performance [1][3]

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Hims & Hers and cert ...

Core Viewpoint - A class action lawsuit has been filed against Iovance Biotherapeutics, Inc. concerning allegations of securities fraud and unlawful business practices [2][4]. Financial Performance - Iovance reported a total product revenue of $49.3 million for Q1 2025, down from $73.7 million in the previous quarter, indicating a significant decline [4]. - The company revised its full fiscal year 2025 total product revenue guidance from a range of $450 million - $475 million to $250 million - $300 million, representing a reduction of over 40% at the midpoint [4]. - The updated revenue forecast reflects recent launch dynamics affecting Amtagvi, the company's lead product candidate, and considers growth trajectories and treatment timelines for new authorized treatment centers (ATCs) [4]. Stock Market Reaction - Following the financial results announcement, Iovance's stock price fell by $1.42 per share, or 44.79%, closing at $1.75 per share on May 9, 2025 [4].

NEW YORK, June 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Neogen Corporation (“Neogen” or the “Company”) (NASDAQ: NEOG).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.    The investigation concerns whether Neogen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On June 4, ...

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Hims & Hers Health, Inc. regarding potential securities fraud or unlawful business practices [1] - Novo Nordisk has discontinued its partnership with Hims & Hers due to non-compliance with legal regulations concerning the sale of compounded drugs, which has raised patient safety concerns [3] - Following the announcement of the partnership termination, Hims & Hers' stock price dropped by $22.24, or 34.63%, closing at $41.98 per share [3] Company Overview - Hims & Hers Health, Inc. is publicly traded on the NYSE under the ticker symbol HIMS [1] - The company has faced scrutiny regarding its business practices, particularly in relation to the sale of compounded drugs [3] Legal and Regulatory Context - The investigation by Pomerantz LLP suggests potential legal challenges for Hims & Hers, which may impact investor confidence [1] - Novo Nordisk's decision to end the partnership highlights regulatory compliance issues that could affect Hims & Hers' operations and reputation [3]

Core Viewpoint - Altimmune, Inc. is under investigation for potential securities fraud following the release of mixed results from a clinical trial, which led to a significant drop in its stock price [1][2]. Group 1: Investigation and Legal Context - Pomerantz LLP is investigating claims on behalf of investors of Altimmune regarding possible securities fraud or unlawful business practices by the company and its officers or directors [1]. - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [3]. Group 2: Clinical Trial Results and Market Reaction - On June 26, 2025, Altimmune announced "topline results" from the IMPACT Phase 2b trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH), describing the results as "positive" [2]. - The trial reported fibrosis improvement rates of 31.8% and 34.5% for pemvidutide doses of 1.2 mg and 1.8 mg, respectively, compared to 25.9% for placebo, with the differences not being statistically significant [2]. - Following the announcement, Altimmune's stock price fell by $4.10, or 53.18%, closing at $3.61 per share on the same day [2].

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. concerning allegations of securities fraud and unlawful business practices [2][3]. Group 1: Lawsuit Details - The lawsuit involves claims that Hims & Hers and certain officers/directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Hims & Hers securities during the Class Period have until August 25, 2025, to request to be appointed as Lead Plaintiff [3]. Group 2: Partnership and Stock Impact - On April 29, 2025, Hims & Hers announced a collaboration with Novo Nordisk to sell a bundled offering of Wegovy® [3]. - On June 23, 2025, Novo Nordisk terminated its partnership with Hims & Hers, citing deceptive promotion and selling of illegitimate versions of Wegovy® that jeopardized patient safety [3]. - Following the termination announcement, Hims & Hers' stock price dropped by $22.24, or 34.63%, closing at $41.98 per share [3].

Group 1 - Edgewise Therapeutics is under investigation for potential securities fraud or unlawful business practices involving its officers and/or directors [1] - The company reported clinical trial data for its lead asset, sevasemten, indicating "positive" results for Becker and Duchenne muscular dystrophies, but the FDA deemed the data insufficient for accelerated approval [2] - Following the announcement, Edgewise's stock price decreased by $1.27 per share, or 8.86%, closing at $14.33 per share [3] Group 2 - Pomerantz LLP is a prominent firm specializing in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving PetMed Express, Inc. and its officers or directors [1] Group 1: Company Actions - On June 10, 2025, PetMed announced a delay in releasing its fourth quarter and fiscal year 2025 earnings due to the need for additional time to complete the year-end audit process [2] - Following the announcement, PetMed's stock price dropped by $0.47 per share, or 11.22%, closing at $3.72 per share on June 11, 2025 [2] Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [3]